On the Pulse of
Precision
Cancer
Treatment

Learn More
Mirai Medical logo white
Scan of Gastrointestinal Therapy

Gastrointestinal Therapy

ePORE® therapy is a precision cancer treatment addressing critical unmet challenges and symptom relief for gastrointestinal cancers.
For Patients
For Clinicians
Medical professional examining a patients back and neck area

Skin Therapy

Delivered under local anaesthesia as a day case procedure, ePORE® therapy can be used in combination with chemotherapy for the local control of a wide range of skin cancers.
For Patients
For Clinicians
Scan of Gastrointestinal Therapy

Gastrointestinal Therapy

ePORE® therapy enables every endoscopist to treat at diagnosis
For Patients
For Clinicians

Value Award Winners

Play Video

How It Works

ePORE Therapy how it works video thumbnail
Please accept marketing cookies to view this video.
Dr Declan Soden's mission speech in graphic

Addressing critical unmet challenges in gastrointestinal disease

In Europe an estimated 15% of new cases and 13.7% of deaths will be due to Colorectal Cancer by 2040
European Cancer Information System. (2021). Colorectal Cancer Burden in EU-27. Brussels: European Commisson.
Early-onset Colorectal Cancer, affecting individuals less than 50 years old is on the rise, particularly in high-income countries
Akimoto, N. (2020). Rising incidence of early- onset colorectal cancer — a call to action. Nature Reviews Clinical Oncology, https://doi.org/10.1038/s41571-020-00445-1
In the USA, Colorectal Cancer had the greatest increases in the number of incident cases of young onset GI cancer in 2019.
Reference: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2808381

Targeted Therapy
Big Results.

Icon depicting improved patient experience

Precision Based Treatment

  • Minimal side effects
  • Reduces/stops bleeding associated with GI cancers
  • Precision-based technology, so only targets tumour tissue, thereby preserving healthy tissue
  • Preserves cosmesis and function of treated area
Icon of a hand holding cash

Cost Effective Treatment

  • Can be performed under local anaesthetic therefore reducing cost associated with the procedure.
  • Patients are treated as a day-case procedure which reduces time spent in hospital.
Icon of a hand holding a lightbulb

An Alternative Treatment

  • Alternative treatment for those who are at risk of going under general anaesthetic or suffer with comorbidities
  • Can be used in conjunction with other standard treatments (chemotherapy, surgery)
  • Repeatable - the treatment can be repeated multiple times in order to ensure effective removal of the tumour

Years of Experience

We bring together some of the best minds in electroporation and therapeutic development expertise.

DR Declan Soden Founder & CEO of Mirai Medical
Dr. Declan Soden
Founder & Chief Executive Officer
Colin Forde
Chief Operating Officer
Simon Ombler, sales and marketing director at Mirai Medical
Simon Ombler
Sales & Marketing Director
Seán Kinsella
Chief Technical Officer

Patient Experience

Hear about the positive experience of a skin cancer patient who underwent ePORE® therapy treatment.

Please accept marketing cookies to view this video.

Recent News

Digestive Disease Week 2024
Read More
MIRAI MEDICAL supports the British Society for Dermatological Surgery (BSDS)
Read More
Celebrating 60 Years of the European Society of Gastrointestinal Endoscopy
Read More

Follow Our Progress

By clicking submit, you agree to receive communications and updates from Mirai Medical, and acknowledge Mirai Medical's Privacy Policy.
This field is for validation purposes and should be left unchanged.

Contact Us

By clicking send, you confirm you have read and agreed to Mirai Medical's Privacy Policy.
Twitter Linkedin-in Youtube
ePORE Therapy White Logo
Address:
Mirai Medical
Unit 5, Howley Court
Oranmore
Galway
Ireland
Email:
info@mirai-medical.com
Mirai Medical logo white
© Copyright 2024 MIRAI MEDICAL. All Rights Reserved.
Privacy & Cookies
ePORE® therapy, EndoVE® and CUTIS are approved for commercialisation in the European Union, United Kingdom and Australia. ePORE® therapy, EndoVE® and CUTIS are not cleared by FDA for commercialisation in the USA.
WEEE Ireland Certificate of Registration MIR 100
PRL Registration Number: IE 02581 WB
Website by Proactive Design & Marketing